Intas Pharmaceuticals Ltd has launched a generic version of romiplostim for the treatment of chronic idiopathic thrombocytopenia purpura (ITP) in India recently.
Sold under the brand name Nplate by Amgen, romiplostim was approved by USFDA in 2008 as a long-term treatment for chronic ITP in adults who have not responded to other treatments, such as corticosteroids, intravenous immunoglobulin, Rho(D) immune globulin or splenectomy.
A fusion protein analogue of thrombopoietin, romiplostim, is one of the most efficacious agents with proven long-term benefits in chronic ITP.
The standard of care therapy currently costs around Rs.60,000 per month, according to reports.
Intas’ romoplostim (Romy) is priced at Rs.2,995 for a dose of 250 mcg, which comes around Rs.12,000 for a month’s treatment.
Around 42,000 patients are diagnosed with ITP in India every year, it is estimated. Less than 10% of patients which include adults as well as children, have access to the treatment which is required to maintain adequate platelet counts for a longer duration. In ITP, long term use of drugs is required to maintain adequate platelet count.
Chronic ITP is an autoimmune blood disorder which leads to low platelet counts. Platelets are responsible for the clotting of blood, and a reduced platelet count can lead to life- threatening bleeding complications, including bleeding in the brain.